Figure 1
Maraviroc induces a dose-dependent decrease in mucosal inflammation in DSS Colitis.
Mice were administered DSS (5%) in drinking water for 5 days and then treated with placebo or maraviroc (5, 25 or 50 mg/kg/d) or prednisolone (5 mg/Kg/d) for 4 days starting on day 2. (A) The disease activity index (DAI) was calculated daily for each individual mouse based on weight loss, rectal bleeding and stool consistency. (B,C) Macroscopic injury (lesion area in mm2) and colon length. (D) MPO activity (mU/mg protein). (E) Histopathology analysis of colon in mice administered DSS alone or in combination with maraviroc or prednisolone. Data Are mean ± SE of 5 mice per group. (F) Assessment of tissue biomarkers by Bio-Plex® Multiplex immunoassay. Data were normalized to total tissue proteins. In each panel at least 5 animals per group are included. Markers for the Th1 phenotype are labeled in blue, for Th2 phenotype in violet and for regulatory phenotype/chemokine in black. *P < 0.05 versus control; **P < 0.05 versus DSS.
